Bliss GVS Pharma Limited (NSE:BLISSGVS)
India · Delayed Price · Currency is INR 652.35
-2.40 (-0.37%)
Nov 11, 2026, 1:20 PM IST
Bliss GVS Pharma Revenue
Bliss GVS Pharma had revenue of 3.13B INR in the quarter ending September 30, 2026, with 28.22% growth. This brings the company's total for the last twelve months to 10.74B, up 24.87% year-over-year. In the fiscal year ending March 31, 2026, Bliss GVS Pharma had annual revenue of 9.27B with 14.50% growth.
Revenue (ttm)
10.74B
Revenue Growth
+24.87%
P/S Ratio
6.32
Revenue / Employee
10.40M
Employees
1,033
Market Cap
68.98B
Revenue by Geography
- Outside India 8.50B 92.7%
- India 673.41M 7.3%
Fiscal year ended Mar 31, 2026 See the full Bliss GVS Pharma breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 9.27B | 1.17B | 14.50% |
| Mar 31, 2025 | 8.10B | 394.81M | 5.13% |
| Mar 31, 2024 | 7.70B | 186.57M | 2.48% |
| Mar 31, 2023 | 7.52B | 41.33M | 0.55% |
| Mar 31, 2022 | 7.47B | 1.70B | 29.50% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Strides Pharma Science | 52.13B |
| Akums Drugs and Pharmaceuticals | 48.29B |
| NATCO Pharma | 34.85B |
| Aarti Pharmalabs | 19.69B |
| Sun Pharma Advanced Research Company | 19.32B |
| Innova Captab | 17.49B |
| Solara Active Pharma Sciences | 15.35B |
| Orchid Pharma | 8.52B |
Bliss GVS Pharma News
- 13 days ago - Bliss GVS Pharma Quarterly report: Q2 2027 - Filings
- 3 months ago - Bliss GVS Pharma Quarterly report: Q1 2027 - Filings
- 4 months ago - Bliss GVS Pharma appoints Rahul Adakmol as CEO effective July 15, 2026 - Business Upturn
- 4 months ago - Bliss GVS Pharma announces book closure and record date for dividend payment - Business Upturn
- 4 months ago - Bliss GVS Pharma announces Re. 1 final dividend per share for FY 2025-2026 - Business Upturn
- 5 months ago - Anupam Rasayan makes Rs 299 per share open offer for Bliss GVS Pharma - Business Upturn
- 5 months ago - Bliss GVS Pharma faces Rs 299 per share open offer from Anupam Rasayan - Business Upturn
- 5 months ago - Bliss GVS Pharma achieves WHO-GMP compliance for manufacturing facility - Business Upturn